Evaluation of satisfaction and preference in patients with osteoporosis receiving Denosumab

Abstract

Satisfaction and preference properties differ in osteoporosis treatment agents. In our study we aimed to evaluate these properties in patients receiving denosumab treatment. Material and methods: Thirty female patients who had denosumab injections were included in our study. Demographic and general characteristics were recorded. General patient satisfaction, patient satisfaction of the drug and it's effect on quality of life was evaluated on a Likert scale. Patients' preference was evaluated with asking the reasons of switches to denosumab. Results: The mean age of patients was 59.30±12.86 years. Of the patients 30 (% 100.0) wanted to continue the same therapy, 25 (%83.3) patients stated that managing this treatment is extremely easy. 25 (% 83.3) patients stated that it was extremely well-suited with lifestyle. 25 (% 83.3) patients were extremely convenient to take medication. 25 (% 83.3) patients have extremely willed to continue to use the medication. Of 30 patients, 30 (% 100) have been switched to denosumab due to physician recommendation. Physician recommended have been done to these patients due to ineffectivity of previous osteoporosis treatments or due to side effects of previous osteoporosis treatments. 22 (%73.33) of these patients have been switched to denosumab due to ineffectivity of previous osteoporosis treatments. About 8 (%26.66) patients have been switched to denosumab due to side effects of previous osteoporosis treatments. Conclusion: Denosumab treatment in osteoporosis is a convenient and well-tolerated therapeutic modality.